Yuval Shaked (PhD) is an Assistant Professor and Senior Lecturer at the Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Israel.

He obtained his PhD from the Department of Neurology at Hadassah University Hospital (Israel) where he studied biochemical aspects of neurodegenerative disorders.

Subsequently, he was trained at Sunnybrook Health Sciences Centre, University of Toronto, Canada, and studied cancer biology under the supervision of Robert S. Kerbel, a leading scientist in the field of metronomic chemotherapy. In particular, he evaluated bone marrow derived proangiogenic cells (BMDCs) as possible surrogate biomarkers to monitor biologic activity and determine the optimal biological dose of antiangiogenic drugs and metronomic chemotherapy regimens. He also explored the contribution of certain types of BMDC populations to tumor angiogenesis after treatment with various anti-cancer drugs. Currently, his research program aims to study tumor cell biology and growth in the context of angiogenesis, tumor invasion and metastasis, the tumor microenvironment, and cancer stem cells (CSCs). A major focus of his laboratory is to explore angiogenesis and metastasis associated with circulating BMDCs, and the impact several types of chemotherapy or treatment regimens on metastasis growth. In addition, he investigates the effects of newly developed targeted anti-cancer drugs on tumor cell growth in terms of BMDC mobilization and colonization of tumors, metastasis spread, and CSCs expansion. He also studies the impact of host bone marrow responses on tumor growth after various drug treatments and different treatment regimens and seeks alternative ways to improve treatment outcome.